Novo Nordisk's icodec therapy delivers positive data - PharmaTimes
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Prediction: This Could Be This Company's Next Billion-Dollar Product | Nasdaq
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo afslutter sidste af seks succesfulde studier med ugentlig insulin - Dagens Medicin
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Once-weekly insulin efficacy similar to daily therapy in type 2 diabetes
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin — MedWatch
Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduct
Novo Nordisk once-weekly insulin icodec beats Tresiba, matches Sanofi's Lantus in trials | Seeking Alpha
Primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin
Novo Nordisk tees up phase 3 trial for once-weekly insulin | Fierce Biotech
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Once-Weekly Insulin Icodec Promising for Type 2 Diabetes - Consumer Health News | HealthDay
